News Novo Nordisk obesity drug linked to rare cause of sight loss The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
News MHRA advises contraception for women taking 'skinny jabs' Women in the UK taking weight-loss injections have been warned by the MHRA that they should make sure they are using effective contraception.
News FDA tightens heart tox warnings on mRNA COVID vaccines The FDA has instructed Pfizer and Moderna to add stronger warnings to the labels of their COVID-19 vaccines about the risk of cardiotoxicity.
News France probes side effects with Valneva's chikungunya jab France's national public health agency has halted dosing of Valneva's chikungunya vaccine in older people while it investigates a safety signal.
News GSK reprimanded over "shocking error" in Omjjara info A complaint against GSK alleging a major breach of the pharma industry's code of practice on prescribing information has been upheld by the PMCPA.
News Pfizer's weight-loss aspirations are dealt a heavy blow Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face